2,4,5-三碘咪唑 | 1746-25-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2,4,5-三碘咪唑
• 中文别名: 2,4,5-三碘-1H-咪唑
• 英文名称: 2,4,5-triiodoimidazole
• 英文别名: 2,4,5-triiodo-1H-imidazole；tri-iodoimidazole
• CAS: 1746-25-4
• 化学式: C₃HI₃N₂
• mdl: MFCD00068812
• 分子量: 445.768
• InChiKey: HIDCNJIBRZBEPN-UHFFFAOYSA-N

物化性质

• 熔点：
  188-190°C
• 沸点：
  459.2±50.0 °C(Predicted)
• 密度：
  3.504±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  6.1
• 安全说明：
  S26,S37/39
• 海关编码：
  2933290090
• 危险品标志：
  Xn
• 危险类别码：
  R22,R36/37/38
• 危险品运输编号：
  UN 2811 6.1/PG III
• RTECS号：
  NI8680000
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P264,P270,P280,P301+P310+P330,P302+P352+P332+P313+P362+P364,P305+P351+P338+P337+P313,P405,P501
• 危险性描述：
  H301,H315,H319
• 储存条件：
  存放于惰性气体中，并避免光照和接触空气。

SDS

Name:	2 4 5-Triiodo-1h-imidazole 97% Material Safety Data Sheet
Synonym:
CAS:	1746-25-4

Section 1 - Chemical Product MSDS Name:2 4 5-Triiodo-1h-imidazole 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1746-25-4	2,4,5-Triiodo-1H-imidazole	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1746-25-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: beige
Odor: odorless - slight odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C3HI3N2
Molecular Weight: 445.76

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen iodide, iodine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1746-25-4: NI8680000 LD50/LC50:
CAS# 1746-25-4: Oral, rat: LD50 = 278 mg/kg.
Carcinogenicity:
2,4,5-Triiodo-1H-imidazole - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 22 Harmful if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 1746-25-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1746-25-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1746-25-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,4,5-三碘咪唑 在 Oxone 作用下， 以 水 为溶剂， 以55.6%的产率得到2,4,5-triiodylimidazole
  参考文献：
  名称：

  低爆炸压力的富含碘的致密化合物作为杀菌剂

  摘要：

  制备了十五种碘化合物和六种碘化合物，其碘含量在45.3％至89.0％之间。通过使用Oxone，从相应的碘代化合物获得单，二和三碘基化合物。所有化合物均通过IR，1 H和13 C NMR，元素分析和差示扫描量热法（DSC）表征。冲击敏感度通过使用BAM（BundesamtfürMaterialforschung）方法进行测量。根据计算出的地层热和实验密度，采用Cheetah 6.0预测了爆轰性能和爆轰产物。含碘物质的总百分比（wt％）（I 2，HI和气相中的I）范围为46.7（21）至88.94％（11）被发现在爆炸产物中。碘和/或含碘物种的高浓度和易获取性对于开发适合用作特工击败武器（ADW）的材料非常重要。

  DOI：

  10.1002/chem.201300565
• 作为产物：
  描述：

  咪唑 在 sodium hydroxide 、 碘 、 potassium iodide 作用下， 生成 2,4,5-三碘咪唑
  参考文献：
  名称：

  美托咪定类似物为α2-肾上腺素配体。2.美托咪定的构象受限的萘衍生物的设计，合成和生物学活性。

  摘要：

  已制备了一系列新的美托咪啶萘类似物，并对其α-肾上腺素能进行了评估。甲基萘类似物5a对α2肾上腺素受体具有明显的选择性，并在大鼠主动脉制剂中充当部分α1激动剂。相反，Z-乙烯类似物8c是α1选择性的，并且表现为有效的α1拮抗剂。两个刚性类似物（6和7）在α1-VSα2受体的结合亲和力上显示出很大差异，表明5a的构象柔韧性对于实现α-肾上腺素能活动很重要。分子建模研究始于经典苯乙胺和美托咪定类似物的构象分析。美托咪定构象与苯乙胺构象的叠加为新咪唑的α2-肾上腺素活性提供了一个初步的解释。提出了一种常见的苯乙胺和咪唑与α2肾上腺素能受体的结合方式。对4-取代的咪唑的生物学特性的了解与计算机辅助分子建模衍生的信息相结合，为此类作为新的肾上腺素能药物的结构和构象要求提供了新的见识。

  DOI：

  10.1021/jm9506074
• 作为试剂：
  描述：

  甲基-4-O-苯甲酰基-6-脱氧-6-溴-α-D-吡喃葡萄糖苷 在 吡啶 、 咪唑 、 2,4,5-三碘咪唑 、 三乙基硼氢化锂 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 100.5h， 生成 methyl-4-O-acetyl-2,3,6-tridesoxy-α-D-threo-hex-2-enopyranoside
  参考文献：
  名称：

  钯催化不饱和糖的烯丙基胺化的应用：d-山梨糖胺的新合成

  摘要：

  由甲基4，6-O-亚苄基-α-d-吡喃葡萄糖苷（1）获得的甲基4-O-苯甲酰基-6-溴-6-脱氧-α-d-吡喃葡萄糖苷被转化为2，3-不饱和的通过使用三碘咪唑方法制得4-苯甲酸酯（3）。3的脱苯甲酰化，然后乙酰化，得到结晶的甲基4-O-乙酰基-6-溴-2,3,6-三苯氧基-α-d-赤型-己基-2-烯吡喃糖苷（5）。在钯催化的烯丙基取代条件下用苄基甲胺处理5，得到相应的4-（N-苄基）甲基氨基-6-溴-2-烯苷（37％）和4,6-二-[[ （N-苄基）甲基氨基] -2-烯苷（55％）。用三乙基硼氢化锂将5脱溴，同时进行脱乙酰基反应，很容易得到甲基2,3,6-丁氧基-α-d-赤型-己基-2-烯吡喃糖苷（8）。8的4-乙酸盐（通过重新乙酰化获得），以及它的4-苯甲酸酯（通过不同的合成方法制得），提供了4-[（（N-苄基）-甲基氨基] -2,3,4,6-四脱氧-α-d甲基的高收率（〜80％）钯催化

  DOI：

  10.1016/s0008-6215(00)85594-9

文献信息

• [EN] OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS<br/>[FR] DERIVES D'OXAZOLIDINONE UTILISES COMME AGENTS ANTIMICROBIENS
  申请人：RANBAXY LAB LTD

  公开号：WO2006038100A1

  公开（公告）日：2006-04-13

  The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria, for example, multiple-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms, for example, Bacterioides spp. and Clostridia spp. species, and acid fast organisms, for example, Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.

  本发明涉及某些取代苯基噁唑烷酮以及其合成方法。本发明还涉及含有本发明化合物作为抗微生物药物的药物组合物。这些化合物是有用的抗微生物剂，对多种人类和兽医病原体有效，包括革兰氏阳性厌氧细菌，例如多重耐药葡萄球菌、链球菌和肠球菌，以及厌氧生物，例如Bacterioides属和Clostridia属物种，以及耐酸生物，例如结核分枝杆菌、埃维分枝杆菌和分枝杆菌属。
• BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE
  申请人：Heffron Timothy

  公开号：US20120245144A1

  公开（公告）日：2012-09-27

  Benzoxazepin Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  本句翻译为中文是：苯并恶唑啉I型化合物，包括立体异构体、几何异构体、互变异构体、代谢物以及药学上可接受的盐，对于抑制PI3K的δ异构体以及治疗由脂质激酶介导的疾病如炎症、免疫疾病和癌症是有用的。公开了使用I型化合物公式进行体外、原位和体内诊断、预防或治疗哺乳动物细胞中此类疾病或相关病理状况的方法。
• [EN] TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE<br/>[FR] DÉRIVÉS DE TÉTRAHYDROQUINOLINE ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011054841A1

  公开（公告）日：2011-05-12

  Tetrahydroquinoline compounds of Formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

  Formula (I)的四氢喹啉化合物及其盐，含有这种化合物的药物组合物以及它们在治疗中的用途。
• Tetrahydroquinoline Derivatives And Their Pharmaceutical Use
  申请人：Demont Emmanuel Hubert

  公开号：US20120208798A1

  公开（公告）日：2012-08-16

  Tetrahydroquinoline compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

  公式（I）的四氢喹啉化合物及其盐，含有这种化合物的药物组合物以及它们在治疗中的用途。
• A simple method for iodination of heterocyclic compounds using HIO4/NaCl/silica gel/H2SO4 in water
  作者：Abolfazl Hosseini、Mohammad A. Khalilzadeh、Masoumeh Hosseinzadeh、Mahmoud Tajbakhsh

  DOI：10.1007/s00706-011-0611-6

  日期：2012.4

  AbstractA fast and simple method for iodination of some heterocycles is reported. The reactions were carried out in water, using HIO4/H2SO4/NaCl/silica gel at moderate temperatures of 25–50 °C. Graphical Abstract

  摘要报道了一种快速简单的碘化某些杂环的方法。反应在25–50°C的中等温度下使用HIO 4 / H 2 SO 4 / NaCl /硅胶在水中进行。 图形概要